Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CMRX

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Benzinga · May 16, 2022

Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract

Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract

In its SEC filing, Chimerix Inc (NASDAQ:CMRX) announced that it had been aware of unusual trading activity in the Company's common stock. The Company believes the unusual trading activity may be attributable to statements regarding smallpox antiviral development and procurement contained in the Fiscal Year 2023 Congressional Justification for the Public Health…

Benzinga · Apr 14, 2022

Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies

Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies

Chimerix Inc's (NASDAQ: CMRX) preclinical data from its CMX521 program will be featured at the International Conference on Antiviral Research (ICAR) in March.

Benzinga · Feb 24, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Benzinga

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

420,990 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play